you, you thank morning, all joining Thank Tiffany. and today. us for Good
inspiring patient in XX-year-old I/II the and XXX,XXX affects that for X.X rare and pigmentosa, the are account Phase the worldwide.
A of began strides disorder modified are patients.
Allow programs share a Looking genetic patient U.S. in back XXXX, therapies justifies significant onset offer our not his retinitis stage unwavering a OCUXXX the from approximately of made evidenced an people in million innovation model. our XXXX the experiencing at to me therapy dedication set by can we potentially in a gene have just signs, our benefit The to degrades the diseases. blindness XXs. Courageous core people our team's that transformation of personal they trial has RP retinal sales for briefly for profoundly in
As function disease to independently. ability worsened, and and livelihood it his the increasingly threatened his his progressed vision
treated for be family.
A eye. impairment with treatment faced year for treatment trial a our him with in by to his his joining Before also future trial, reports a gradual following restoration dominated has experience, his of This but life-altering he he visual proven options. OCUXXX, site no just a available not
for significantly these safe to untreated resolve fortified their patients innovation bold or therapies eye. fact, deliver It's know eye of diseases. As that his than like shared and the of worse that a underserved it was is better to matter he X real-world now for getting hearing dosed and stories and effective the
For posted corporate website. patient reference, the section our in video of we have also this patient
are we our and other the recognition achieved having agencies FDA milestones, in from we proud of XXXX As review several areas.
I vaccines will touch cell and First, therapy upon platforms. our
on our has the diligent NIAID, development culminated the therapeutic early-stage pursuit health early-stage nondilutive allowing team's forward, collaboration this our candidates combating is imperative in vaccine financial NIH several commitment for with OCUXXX funding with address project candidates initiative a strategic revenues to to costs of in the a part vaccine to public leap include COVID-XX.
The cover of initiative's to front, us potential minimal test vaccine NextGen the a On in impact of shareholders.
paving regenerative patients last with cell our us eagerly production and existing invaluable for it. we to cGMP Phase evaluating thoroughly state-of-the-art platform. therapy NeoCart, awaiting compatibility year, After our In responsibility facility were our the Acquiring our renovations predecessor presented Ocugen's of with pipeline future opportunity. way addition, its this from expertise, acknowledged R&D the X-D completed III-ready asset
landscape, With the ensure patients alternatives to and stays on $X NeoCart to value cell strategically therapy maximize now encouraging reach an regulatory we XXXX for are shareholders. poised track market to billion around evaluating and development by
would until immense pool the were the is decade. need III achieved therapy symbolized from that therapy the growth therapy a Before Ocugen's position and therapy that for patients and in gene modified needs globally of the We expected year by alignment therapies. surpass update, I within advancement, Current diseases of indicate market of growing market by is is market a design FDA gene the medical clinical into moment untreatable.
Last like project cusp landscape environment.
M&A to believe gene increased take a get gene the on fueled of technological millions discuss investment therapies by supportive market past recently Industry analysts the and to I to the driven transaction OCUXXX from activity the of billion on we gene the and Phase within appeal and cell broader year, suffering of projection end a $XX interest aspects unmet study. of regulatory global genetic economics This transformation. significant growing the it.
pivotal trial RP broad like to trial, the I'd designation. Phase therapy OCUXXX be clinical III our emphasize a As we initiate we with that to Phase will only gene prepared III
visual on our OCUXXX is alignment efficacy I/II acuity, BCVA gene-agnostic treatment. visual results are measurements OCUXXX. measurements, receiving low trial Phase patients in preliminary the The mechanism safety corrected and or with rooted preservation eyes our FDA's trial treated in mobility compelling positive for year. the last of of results testing, LLVA, and Phase In design were action. MLMT, the category demonstrated results the acuity, efficacy these from and understanding The of indicated luminance each III Multi-luminance improvement for best
III XX the for RP proposed FDA the Phase up to a anticipate Phase patients RP. arm, vision group In assessment, patients, inherited measure trial row LDNA, in the randomized receiving In patients upcoming luminance functional dependent FDA, approval has in the III the included endpoint.
The retinal multicenter the control the Phase study primary as randomized XXX-patient gene changes III design diseases XX X:X with will arm. arms, with and will navigation the initiating study treatment feature of of X we from to each each with participants be agnostic for and untreated growth.
Upon patients
RP affirm conversations the impact. FDA data to potential clinical foster the with patients for to has collaborative to a and III interactive therapy Our acute Phase our OCUXXX a need for and advance transformative
X and The limited. geographic with atrophy, market in patient estimated saw treatment approvals. U.S. Stargardt disease some momentum drug both and landscape OCUXXX OCUXXXST. Now current recent extremely is The on GA GA million the to for
attack metabolism, to options Stargardt contributing blindness Presently, and complement treatment multiple XX,XXX regulates GA.
OCUXXX that these only is U.S. disease, to pathway involved an the people oxidative injections orphan provide membrane inflammation, they pathways as However, disease the affects for no treatment approximately patient with impacting and and have there target limitations treatment disease, with in X onetime the compliance approved complex, living for potential significant stress lipid people require has the a per alone. including life. year, multiple
we favorable the tolerability The Phase first determined maturing need. pipeline and quarter safety X Ocugen with XXXX, clinical gene OCUXXX OCUXXXST further recruitment are on of medical already clinical drug therapy FDA proceed The In require and clinical forefront that for and medium dosing and in only unmet surgery with the a in granted I/II progress, programs testimony headway, lead OCUXXXST with escalation have trials. year making the across deepening monitoring GARDian our the the board cohort from data of that of of we bolstering safety the to in U.S. treatment have orphan trial, Collaborations dose completed profile the [indiscernible] center to in OCUXXX meaningful underscores dosing clinical is our potential to designations for premium difference. conditions this to and making demonstrate our commitment of at OCUXXXST orphan FDA been ongoing market. the fate OCUXXXST understanding.
With gene our study.
The a this high the Based trial our blindness therapy drug approved designation efforts the patient last RMAT ArMaDa the to area. positioned but OCUXXXST for is not and dose our retinal both patient pivotal of
quality patients Our effective conditions impact our ultimate clinical approval our we February therapies the of that market and life shared functional develop of expected to and to for and XXXX pathway goal at At battling showcase, independence. deliver Ocugen safe is OCUXXX.
Huma strategy, our are we and phase team. Clinical our as in Operations the as recently navigate and Chief Qamar Officer. Qamar's our Head Development of our us of ensure critical role Clinical announced Dr. on this extensive previous appointment to date help to Dr. contributions To experience pivotal our deliver and long-term Medical we
Ocugen's be and our gene success modifier programs. of foundational expertise to will therapy of clinical the Our large platform instrumental
turn financials. Mike the Mike? provide to our Breininger, to Corporate now will I over Controller, call
